Person: ŞİMŞEK, MELİH
7 results
Search Results
Now showing 1 - 7 of 7
Publication Open Access Breast Cancer Patients with Brain Metastases: A Cross-Sectional Study.(2022-08-19T00:00:00Z) Simsek, MELİH; Aliyev, Altay; Baydas, Tuba; Besiroglu, Mehmet; Demir, Tarik; Shbair, Abdallah Tm; Seker, Mesut; Turk, H Mehmet; ŞİMŞEK, MELİH; TÜRK, HACI MEHMETThe prognosis of breast cancer patients with brain metastasis is poor. It was aimed to define the clinicopathological features of breast cancer patients with brain metastases and to determine the risk factors and survival outcomes associated with brain metastasis. This is a single-center, retrospective, cross-sectional study. A total number of 127 patients diagnosed with breast cancer and who developed brain metastasis between January 2011 and March 2021 were retrospectively analyzed. The survival and clinicopathological data of these patients according to 4 biological subtypes were evaluated (luminal A, luminal B, HER-2 overexpressing, and triple-negative). The median overall survival for all patients was 45.6 months. The median time from the diagnosis of breast cancer to the occurrence of brain metastasis was 29.7 months, and the median survival time after brain metastasis was 7.2 months. The time from the diagnosis of breast cancer to brain metastasis development was significantly shorter in HER-2 overexpressing and triple-negative subtypes than in luminal A and B subtypes. The median time from breast cancer diagnosis to brain metastasis was 33.5 months in luminal A, 40.6 months in luminal B, 16.8 months in HER-2 overexpressing, and 22.8 months in the triple-negative groups (p=0.003). We found the worst median survival after brain metastasis in the triple-negative group with 3.5 months. Early and close surveillance of high-risk patients may help early diagnosis of brain metastasis and may provide to perform effective treatments leading to longer overall survival times for this patient population.Publication Metadata only Mide kanserli hastaların demografik özelliklerinin sağ kalıma etkisi(2022-05-01T00:00:00Z) Karadeniz, Andaç; Bilici, Mehmet; Şimşek, Melih; ŞİMŞEK, MELİHPublication Open Access Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study(2022-01-01T00:00:00Z) YASİN, Ayşe İrem; Aydin, Sabin Goktas; SÜMBÜL, BİLGE; KORAL, LOKMAN; ŞİMŞEK, MELİH; Geredeli, Caglayan; Ozturk, Akin; Perkin, Perihan; Demirtas, Derya; Erdemoglu, Engin; HACIBEKİROĞLU, İLHAN; Cakir, Emre; Tanrikulu, Eda; Coban, Ezgi; Ozcelik, Melike; Celik, Sinemis; Teker, Fatih; AKSOY, ASUDE; Firat, Sedat T.; Tekin, Omer; Kalkan, Ziya; Turken, Orhan; Oven, Bala B.; Dane, Faysal; Bilici, Ahmet; Isikdogan, Abdurrahman; ŞEKER, Mesut; TÜRK, HACI MEHMET; Gumus, Mahmut; YASİN, AYŞE İREM; SÜMBÜL, BİLGE; ŞİMŞEK, MELİH; ŞEKER, MESUT; TÜRK, HACI MEHMETAim: To compare the seropositivity rate of cancer patients with noncancer controls after inactive SARS-CoV-2 vaccination and evaluate the factors affecting seropositivity. Method: Spike IgG antibodies against SARS-CoV-2 were measured in blood samples of 776 cancer patients and 715 noncancer volunteers. An IgG level ≥50 AU/ml is accepted as seropositive. Results: The seropositivity rate was 85.2% in the patient group and 97.5% in the control group. The seropositivity rate and antibody levels were significantly lower in the patient group (p < 0.001). Age and chemotherapy were associated with lower seropositivity in cancer patients (p < 0.001). Conclusion: This study highlighted the efficacy and safety of the inactivated vaccine in cancer patients.Publication Metadata only Metastatic Breast Carcinoma Mimicking Urothelial Carcinoma(2022-06-01T00:00:00Z) Shbair, Abdallah T. M.; YASİN, Ayşe İrem; TOPÇU, Atakan; ÇOBAN, GANİME; UZUNOĞLU, GÖKÇE DENİZ; ŞİMŞEK, MELİH; YASİN, AYŞE İREM; TOPÇU, ATAKAN; ÇOBAN, GANİME; UZUNOĞLU, GÖKÇE DENİZ; ŞİMŞEK, MELİHBesides being the most frequently diagnosed cancer in women, breast cancer is the main cause of cancer-related deaths in this group of patients. Breast cancer frequently metastasizes to bone, lung, brain, and liver. Renal metastasis from the breast is extremely rare. Here we aimed to report a case of breast cancer with metastasis to bone and left renal pelvis. A 58-year old woman with a mass lesion in the left renal pelvis that mimicked urothelial carcinoma was referred to our clinic. The left nephroureterectomy procedure was performed, and the pathology revealed that a renal pelvis metastasis secondary to breast cancer.Publication Metadata only Malign mezotelyomada kemoterapi uygulamaları(2022-06-01T00:00:00Z) Şimşek, Melih; Işık, Ulaş; Gürbüz, Orkun; ŞİMŞEK, MELİHPublication Open Access The efficacy of BNT162b2 (Pfizer-BioNTech) and CoronaVac vaccines in patients with cancer(2022-05-01T00:00:00Z) ŞİMŞEK, MELİH; Yasin, Ayse; BEŞİROĞLU, MEHMET; TOPÇU, Atakan; SUCUOĞLU İŞLEYEN, ZEHRA; ŞEKER, Mesut; TÜRK, HACI MEHMET; ŞİMŞEK, MELİH; BEŞİROĞLU, MEHMET; TOPÇU, ATAKAN; SUCUOĞLU İŞLEYEN, ZEHRA; ŞEKER, MESUT; TÜRK, HACI MEHMETAlthough vaccination is efficacious and prevents infection in the general population, there is limited data about Coronavirus disease-19 (Covid-19) occurrence after vaccination in cancer patients. It was aimed to evaluate the efficacy of BNT162b2 (Pfizer-BioNTech) and CoronaVac vaccines against Covid-19 in patients with cancer. In this single-center, retrospective, cross-sectional, and descriptive study, the data of cancer patients referred to the medical oncology clinic of a university hospital were analyzed. The sample of the study consisted of cancer patients who had Covid-19 or were vaccinated against Covid-19. A total number of 2578 patients were included in the study. Of the patients, 2000 have never been infected with severe acute respiratory syndrome coronavirus and 578 patients have had a positive reverse-transcription polymerase chain reaction (RT-PCR) for Covid-19. It was found that 2094 patients (81.2%) were fully vaccinated, and 484 patients (18.8%) did not receive full-dose vaccination. A statistically significant difference in Covid-19 occurrence was found between the patients who had full-dose vaccination or not (p = 0.000). In in-group comparisons of full-dose vaccinated patients, while no difference was observed between two doses of BNT162b2 (Pfizer-BioNTech) and three doses of CoronaVac (p = 0.432), a statistically significant difference was observed between all other groups (p < 0.005). When the data of 578 patients who experienced Covid-19 was analyzed, a statistically significant difference was observed between the groups who were full-dose vaccinated and those who were not (p = 0.000). It is recommended that this vulnerable patient group should be prioritized in vaccination programs, and full-dose vaccination (at least two doses of vaccines) should be completed as soon as possible.Publication Metadata only Metachronous bilateral breast cancer diagnosed with primary breast lymphoma and mucinous carcinoma: The first case in the literature(2022-04-01T00:00:00Z) ŞİMŞEK, MELİH; Aykas, Fatma; Yildirim, Ahmet Ozgen; ŞİMŞEK, MELİH© 2022 Journal of Cancer Research and Therapeutics.Introduction: Breast cancer is the most common cancer in women and 2-11% of the cases are bilateral. Bilateral breast cancer frequently emerges as a second primary cancer. Lymphoma and mucinous carcinoma of breast are very rare. Here we present a case, of bilateral breast cancer with metachronous lymphoma and mucinous carcinoma. Case History: 57-year old female had received chemotherapy and radiotherapy for stage IA Diffuse Large B Cell Lymphoma (DLBCL) located in right breast. At 14th month of her breast DLBCL diagnosis, a diagnosis of mucinous carcinoma was determined in her left breast. After surgery, adjuvant anastrozole was initiated. The patient is still in follow-up with remission at her sixth year of DLBCL diagnosis and fifth year of mucinous carcinoma diagnosis. Conclusions: The evaluation of unilateral breast cancer patients in terms of bilateral breast cancer occurrence risk has become important.